{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:12:55Z","timestamp":1794276775588,"version":"4.9.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":140,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101255","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:42:48Z","timestamp":1779493368000},"page":"101255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma"],"prefix":"10.1016","volume":"48","author":[{"given":"Yujiro","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-4264","authenticated-orcid":false,"given":"Atsunari","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishizuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Horitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Inoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Sassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ujike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taigo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctarc.2026.101255_bib0001","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101255_bib0002","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101255_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101255_bib0004","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol."},{"issue":"29","key":"10.1016\/j.ctarc.2026.101255_bib0005","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101255_bib0006","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101255_bib0007","doi-asserted-by":"crossref","first-page":"595.e1","DOI":"10.1016\/j.urolonc.2025.05.016","article-title":"Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: a systematic review and meta-analysis","volume":"43","author":"Gazzoni","year":"2025","journal-title":"Urol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101255_bib0008","article-title":"Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: post hoc analysis of KEYNOTE-052 and LEAP-011","volume":"131","author":"O'Donnell","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101255_bib0009","article-title":"Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan","volume":"7","author":"Kita","year":"2025","journal-title":"ESMO Real. World Data Digit. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101255_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101255_bib0011","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101255_bib0012","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.21873\/anticanres.17267","article-title":"Systemic inflammation indexes and risk of immune-related adverse events in patients with metastatic urothelial carcinoma treated with immunotherapy","volume":"44","author":"Dionese","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2026.101255_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1667155","article-title":"Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?","volume":"17","author":"Cerbone","year":"2026","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101255_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-026-10327-0","article-title":"Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis","volume":"45","author":"Vitale","year":"2026","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101255_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10238-025-02020-3","article-title":"Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: a real-world study from the ARON-2EV project","volume":"26","author":"Rizzo","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101255_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101255_bib0017","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clnesp.2025.10.031","article-title":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): the MOUSEION-012 systematic review and meta-analysis","volume":"70","author":"Vitale","year":"2025","journal-title":"Clin. Nutr. ESPEN."},{"key":"10.1016\/j.ctarc.2026.101255_bib0018","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.2147\/DDDT.S560518","article-title":"Infusion-related reactions among cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-013 systematic review and meta-analysis","volume":"19","author":"Vitale","year":"2025","journal-title":"Drug Devel. Ther."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:54:20Z","timestamp":1790913260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"alternative-id":["S2468294226001668"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101255","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101255"}}